Trading News

Relmada’s stock tumbles 80% after its depressive disorder drug failed a late-stage study


Shares of Relmada Therapeutics Inc.

fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not meet the primary endpoint in a Phase 3 clinical trial. The company said it is still enrolling patients in two other late-stage studies assessing the therapy as an adjunctive treatment. Relmada’s stock is up 40.6% this year, while the broader S&P 500

is down 24.7%.

The 2023 Social Security Raise Will Be Revealed Today. It Could Be Huge for Retirees.

Previous article

British pound jumps on reports UK government may reverse parts of its tax-cutting proposals

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Trading News